Last reviewed · How we verify
Metformin discontinue
This entry represents a discontinuation of metformin therapy rather than a new drug entity.
Metformin is a biguanide that reduces hepatic glucose production and improves insulin sensitivity in peripheral tissues. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Metformin discontinue |
|---|---|
| Also known as | Metformin |
| Sponsor | University of Texas Southwestern Medical Center |
| Drug class | Biguanide |
| Target | AMP-activated protein kinase (AMPK); hepatic glucose production |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin is a biguanide antidiabetic agent that reduces hepatic glucose production and improves insulin sensitivity. The entry 'Metformin discontinue' appears to refer to a clinical decision or study protocol involving cessation of metformin treatment, not a novel pharmaceutical agent. This is not a drug development program but rather a therapeutic intervention.
Approved indications
Common side effects
Key clinical trials
- Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP). (PHASE2)
- A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. (PHASE1)
- Efficacy and Safety of Henagliflozin, Retagliptin, and Metformin Extended-Release Tablets in Chinese Patients With Type 2 Diabetes Mellitus
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Liraglutide Effect in Atrial Fibrillation (PHASE4)
- A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) (PHASE4)
- Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS (NA)
- Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin discontinue CI brief — competitive landscape report
- Metformin discontinue updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI